BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 7869758)

  • 1. Short-term treatment for adult hypergranular and microgranular acute promyelocytic leukemia.
    Bassan R; Battista R; Viero P; d'Emilio A; Buelli M; Montaldi A; Rambaldi A; Tremul L; Dini E; Barbui T
    Leukemia; 1995 Feb; 9(2):238-43. PubMed ID: 7869758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined therapy with all-trans-retinoic acid and high-dose chemotherapy in patients with hyperleukocytic acute promyelocytic leukemia and severe visceral hemorrhage.
    Dombret H; Sutton L; Duarte M; Daniel MT; Leblond V; Castaigne S; Degos L
    Leukemia; 1992 Dec; 6(12):1237-42. PubMed ID: 1453767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Childhood acute promyelocytic leukemia: no benefit of all-trans-retinoic acid administered in a short-course schedule.
    Zubizarreta PA; Rose AB; Felice MS; Alfaro E; Delfino S; Cygler AM; Sackmann-Muriel F
    Pediatr Hematol Oncol; 2000 Mar; 17(2):155-62. PubMed ID: 10734658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of acute promyelocytic leukemia relapse in the ATRA era.
    Castagnola C; Lunghi M; Corso A; Tajana M; Zappasodi P; Dabusti M; Lazzarino M; Bernasconi C
    Haematologica; 1998 Aug; 83(8):714-7. PubMed ID: 9793255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short term therapy (STT) for acute myelogenous leukaemia (AML).
    Rohatiner AZ; Battista R; Bassan R; Love S; Oza AM; Whelan JS; Lim J; Buelli M; Viero P; D'Emillio A
    Leukemia; 1992; 6 Suppl 2():85-8. PubMed ID: 1578952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morbidity and costs of remission induction therapy with all-trans retinoic acid compared with standard chemotherapy in acute promyelocytic leukemia.
    Eardley AM; Heller G; Warrell RP
    Leukemia; 1994 Jun; 8(6):934-9. PubMed ID: 8207987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG.
    Lengfelder E; Haferlach C; Saussele S; Haferlach T; Schultheis B; Schnittger S; Ludwig WD; Staib P; Aul C; Grüneisen A; Kern W; Reichle A; Serve H; Berdel WE; Braess J; Spiekermann K; Wörmann B; Sauerland MC; Heinecke A; Hiddemann W; Hehlmann R; Büchner T;
    Leukemia; 2009 Dec; 23(12):2248-58. PubMed ID: 19741727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
    Esteve J; Escoda L; Martín G; Rubio V; Díaz-Mediavilla J; González M; Rivas C; Alvarez C; González San Miguel JD; Brunet S; Tomás JF; Tormo M; Sayas MJ; Sánchez Godoy P; Colomer D; Bolufer P; Sanz MA;
    Leukemia; 2007 Mar; 21(3):446-52. PubMed ID: 17205057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. All-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL).
    Chim CS; Kwong YL; Liang R; Chu YC; Chan CH; Chan LC; Wong KF; Chan TK
    Hematol Oncol; 1996 Sep; 14(3):147-54. PubMed ID: 9119359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia].
    Xu XJ; Shi SW; Tang YM; Song H; Yang SL; Wei J; Xu WQ; Pan BH; Chen YH; Zhao FY; Shen HQ; Qian BQ; Zhang LY; Ning BT
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):28-33. PubMed ID: 17306073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.
    Tallman MS; Andersen JW; Schiffer CA; Appelbaum FR; Feusner JH; Woods WG; Ogden A; Weinstein H; Shepherd L; Willman C; Bloomfield CD; Rowe JM; Wiernik PH
    Blood; 2002 Dec; 100(13):4298-302. PubMed ID: 12393590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan.
    Ohno R; Ohnishi K; Takeshita A; Tanimoto M; Murakami H; Kanamaru A; Asou N; Kobayashi T; Kuriyama K; Ohmoto E
    Leukemia; 1994; 8 Suppl 3():S64-9. PubMed ID: 7808028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
    Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z
    Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of acute promyelocytic leukemia: a single institution experience.
    Ruiz-Argüelles GJ; Morales-Toquero A; Gómez-Rangel JD; López-Martínez B; Ruiz-Delgado GJ; Reyes-Núñez V
    Rev Invest Clin; 2005; 57(3):415-9. PubMed ID: 16187701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment outcome with chemotherapy in acute promyelocytic leukemia: the Southwest Oncology Group (SWOG) experience.
    Head DR; Kopecky KJ; Willman C; Appelbaum FR
    Leukemia; 1994; 8 Suppl 2():S38-41. PubMed ID: 7815835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of risk factors for fatal hemorrhage during induction therapy of patients with acute promyelocytic leukemia.
    Ventura GJ; Hester JP; Dixon DO; Khorana S; Keating MJ
    Hematol Pathol; 1989; 3(1):23-8. PubMed ID: 2745357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy of disseminated intravascular coagulation in acute promyelocytic leukemias. Apropos of 19 cases].
    Rodríguez Gómez M; López Fernández MF; Batlle J
    Sangre (Barc); 1993 Dec; 38(6):449-53. PubMed ID: 8171380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome.
    Yanada M; Matsushita T; Asou N; Kishimoto Y; Tsuzuki M; Maeda Y; Horikawa K; Okada M; Ohtake S; Yagasaki F; Matsumoto T; Kimura Y; Shinagawa K; Iwanaga M; Miyazaki Y; Ohno R; Naoe T
    Eur J Haematol; 2007 Mar; 78(3):213-9. PubMed ID: 17241371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.